Welcome to our dedicated page for CME GROUP SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CME GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CME GROUP's regulatory disclosures and financial reporting.
CME Group Inc. (CME) – Form 4 insider activity dated 06/25/2025
Director William R. Shepard reported three separate Class A common-stock acquisitions:
- 879 shares were granted under the CME Group Director Stock Plan (transaction code A) with a reference price of $273.03. Shares are held indirectly in a trust. Post-grant indirect holdings: 257,939.99 shares.
- Through a dividend-reinvestment plan, the trust purchased 256.097 shares in the open market (code P) at an average price of $270.53. Indirect holdings after the trade: 258,196.087 shares.
- Shepard’s direct account purchased 11.29 shares at $270.53, raising direct ownership to 2,454.76 shares.
No derivative securities were reported. The filing was signed on 06/26/2025.